[18F]AlF-NOTA-JR11 PET/MR与[68Ga]Ga-DOTA-TATE PET/CT在神经内分泌肿瘤中的头对头比较
41例活检证实的神经内分泌肿瘤患者同期接受[18F]AlF-NOTA-JR11 PET/MR与[68Ga]Ga-DOTA-TATE PET/CT,前者检出924个病灶、后者580个(p<0.001),主要来自肝转移(754 vs 405,p<0.001)。[18F]AlF-NOTA-JR11在原发灶、淋巴结及肝转移中TBR更高,但SUVmax更低,提示其背景摄取更低、更利于病灶显示。
要点
- [18F]AlF-NOTA-JR11 PET/MR检出病灶数显著多于[68Ga]Ga-DOTA-TATE PET/CT(924 vs 580,p<0.001)。
- 额外检出的肝转移灶更小(中位6.00 mm vs 14.00 mm,p<0.001)。
- 原发灶、淋巴结及肝转移TBR更高,但SUVmax更低。
核心结论
- [18F]AlF-NOTA-JR11 PET/MR背景摄取更低,在原发灶、淋巴结转移和肝转移中TBR更高,且检出更多肝转移灶,支持其用于NET患者的临床证据。
研究设计与样本
- 单中心头对头比较研究,纳入41例活检证实的神经内分泌肿瘤患者,均接受[68Ga]Ga-DOTA-TATE PET/CT与[18F]AlF-NOTA-JR11 PET/MR检查。
- 比较两种检查的生理性器官摄取、病灶数目、SUVmax及靶本比(TBR)。
- 试验注册号2020KT15,注册日期2020年3月30日。
主要发现
- [18F]AlF-NOTA-JR11 PET/MR与[68Ga]Ga-DOTA-TATE PET/CT分别检出924个和580个病灶(p<0.001),其中肝转移754个和405个(p<0.001),原发灶29个和25个(p=0.125)。
- 两种检查均检出的405个肝转移灶显著大于仅由[18F]AlF-NOTA-JR11检出的349个病灶(中位直径14.00 mm vs 6.00 mm,p<0.001)。
- 淋巴结转移(p=1.000)和骨转移(p=0.188)检出数无显著差异;基于患者的比较中,76%(31/41)的患者经[18F]AlF-NOTA-JR11 PET/MR检出更多病灶。
- [18F]AlF-NOTA-JR11的病灶SUVmax在原发灶(p=0.002)、肝转移(p=0.017)和骨转移(p=0.008)中显著低于[68Ga]Ga-DOTA-TATE,淋巴结转移中无显著差异(p=0.144)。
- [18F]AlF-NOTA-JR11 PET/MR的TBR在原发灶(p=0.014)、淋巴结转移(p=0.034)和肝转移(p<0.001)中高于[68Ga]Ga-DOTA-TATE PET/CT,骨转移中无显著差异(p=0.343)。
临床怎么用
- 对NET患者,[18F]AlF-NOTA-JR11 PET/MR可检出更多尤其是更小的肝转移灶,并因背景摄取低而提供更高的TBR,有助于病灶显示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs). METHODS: Forty-one patients with biopsy-proven NETs were enrolled and underwent [68Ga]Ga-DOTA-TATE PET/CT and [18F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) were compared between the two examinations. RESULTS: [18F] AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [18F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [18F]AlF-NOTA-JR11 PET/MR than by [68Ga]Ga-DOTA-TATE PET/CT. Lesion SUVmax for [18F]AlF-NOTA-JR11 was significantly lower than that for [68Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [18F]AlF-NOTA-JR11 PET/MR showed higher TBR than [68Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343). CONCLUSION: [18F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [68Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [18F]AlF-NOTA-JR11 PET/MR in patients with NETs. TRIAL REGISTRATION NUMBER: 2020KT15 DATE OF REGISTRATION: 30/03/2020.
引用
- Jin X, Xie Q, Ding X, et al. Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2026. PMID: 42764298. doi:10.1007/s00259-026-08176-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。